Eden vs. Henry Meds: prices, fine print, and the honest verdict

Tirzepatide pricing

On tirzepatide, Henry Meds is the cheaper program at $349 a month all-in versus Eden's $408 — a gap of $59 a month, $708 a year, at the 10 mg maintenance basis. Eden: $408 a month all-in at the 10 mg maintenance basis, dose-scaled from a $348 entry, including the mandatory $99/mo membership. Henry Meds: $349 a month all-in at the 10 mg maintenance basis, flat at every dose from 2.5 to 15 mg, no membership fee. Prepaid terms bring the effective rate to $297/mo (3-month supply paid in full). Prepaid terms reorder things: Henry Meds at $297/mo (3-month supply paid in full) — paid up front, with the regulatory-era caveat that locked-in months deserve a read of the refund terms first.

Semaglutide pricing

On semaglutide, Henry Meds wins at $179 versus $198 all-in — $19/mo apart. Eden: Semaglutide runs $198 a month all-in. Henry Meds: Semaglutide runs $179 a month all-in at the standing rate ($149 on intro/plan terms).

Transparency

Eden: Source-verified (verified 2026-08-05); dispensing pharmacy not publicly named. Henry Meds: Third-party-reported (verified 2026-08-05); dispensing pharmacy not publicly named. In this market, a named pharmacy and a dated, source-verified price are worth real money — they are what let you check the claim instead of trusting it.

Commitment & cancellation

Eden: membership auto-renews; membership auto-renews until cancelled; $99/mo membership recurs until cancelled. Henry Meds: none month-to-month; check terms before prepaying.

The gap, compounded over time

A $59/month difference sounds decidable by coin flip until it's annualized: choosing Eden over Henry Meds at the standing rates costs an extra one month, $59; six months, $354; a year, $708; two years of maintenance, $1,416. Only Henry Meds publishes a prepaid tier ($297/mo effective), which undercuts even Eden's standing $408 by $1,332/year — flexibility versus committed savings, cleanly posed. Every figure is the all-in maintenance basis; the arithmetic reruns from the dataset.

The 24-month ledger

Zoom to the horizon that matters for a chronic-use drug — 24 months — and Eden bills $9,792 and Henry Meds $8,376, a spread of $1,416 for the same molecule at the same 10 mg basis. If prepaid terms held across both years, Henry Meds's $297 effective would total $7,128 — $1,248 under even the cheaper standing plan, with the standing caveat that two years of locked funds in this regulatory climate is a real bet, not a rounding choice. Reference rails for the same 24 months: $5,160 at the verified floor, $10,776 on brand Zepbound at maintenance, $8,376 on Wegovy flat.

Two ladders, side by side

The 2.5-to-10 mg climb is the honest stress test: Eden scales $348 → ~$408 by 10 mg (titration lands between $1,392 and $1,632); Henry Meds holds $349 on every rung (four-month titration: exactly $1,396). A flat ladder makes dose decisions purely clinical; a scaled one attaches an invoice to every escalation — including the post-plateau bump from 10 to 12.5 mg that many patients eventually face. Full framework: the titration cost guide.

Three buyers, two invoices

The month-one starter pays $348 at Eden versus $349 at Henry Meds for the 2.5 mg rung — a wash that the maintenance rates immediately un-wash. The settled 10 mg maintainer — the buyer our basis is built for — pays $4,188/year at Henry Meds against $4,896 at the other: $708 of annual daylight for the same molecule and dose. The committed prepayer does best at Henry Meds: $297/month effective, $3,564/year, funds up front, refund terms first.

The semaglutide board

Henry Meds takes the semaglutide board too at $179 versus $198 all-in — a $19/month, $228/year spread. Both sit against a verified field floor of $133 and Wegovy's flat $349 brand rate; dual-molecule pricing also sets each program's internal switch cost when a plateau raises the tirzepatide question.

The five normalizations, applied to this pair

1 · All-in, not advertised. Eden's ranked figure is $408 ($309 medication + $99 mandatory membership); Henry Meds's ranked figure is $349, with no membership to add. 2 · Maintenance basis. Eden scales from $348 to $408, and the 10 mg figure is the one ranked; Henry Meds is dose-flat, so its entry and 10 mg figures coincide. 3 · Terms separated. Eden: standing $408, no prepaid tier; Henry Meds: standing $349, prepaid $297 effective (3-month supply paid in full) — standing rates rank, prepaid effectives are labeled beside them. 4 · Evidence tiered. Eden: source-verified, read 2026-08-05; Henry Meds: third-party-reported, read 2026-08-05. 5 · Pharmacy weighed. Eden names no pharmacy; Henry Meds names no pharmacy — in a pharmacy-variance market, disclosure is a scored asset. Run the same five on any roundup you read and most published “cheapest” lists reorder themselves.

Fine print, itemized

Eden: a mandatory $99/mo membership folded into our all-in figure; membership auto-renews until cancelled. Henry Meds: no membership — the medication figure is the billed figure; prepaid 3-month supply paid in full at $297/mo effective; check terms before prepaying; commitment: none month-to-month. The pattern to police on both sides is the same: memberships that outlive the medication order, renewal-relative cancellation deadlines, and prepaid terms whose refund language matters more than their discount in a year of live litigation. Cancel in writing; screenshot everything.

Transparency, audited

Eden carries source-verified pricing (last read 2026-08-05); its dispensing pharmacy is not publicly named, so the five pharmacy questions (name, 503A/503B status, state licensure, certificate of analysis, formulation) are your pre-purchase homework. Henry Meds carries third-party-reported pricing (last read 2026-08-05); its dispensing pharmacy is not publicly named, so the five pharmacy questions (name, 503A/503B status, state licensure, certificate of analysis, formulation) are your pre-purchase homework. Our weighting is unapologetic: in a market of identical molecule names, a dated source-verified price and a named pharmacy are the two claims a buyer can actually check, and they carry 25 of 100 formula points between them — the methodology shows the math, and the pharmacy guide decodes every answer the five questions can return.

Switching between them

Neither program locks the door: a Eden-to-Henry Meds move is a new intake, a new prescription at the new pharmacy, and a written cancellation at the old shop — typically a one-to-two-week overlap if you time the last fill. What does not move with you: prepaid months, membership balances, and any dose paperwork, so re-state your current rung clearly at the new intake.

Refills, shipping, and the week-to-week reality

Past the pricing page, the operational facts are what a subscriber lives with: Eden: shipping included; consultation included in membership; async visit model. Henry Meds: shipping included; consultation included; async visit model. Cold-chain shipments run 3–7 days across the market; the recurring failure modes are refill-timing gaps and pharmacy backlogs, so whichever program wins here, order refills a week early and confirm the pharmacy’s current turnaround at intake.

Who should pick which

Pick Eden if its published terms happen to fit your state, format, or timing. Pick Henry Meds if the $59/month tirzepatide saving is the point; the semaglutide line is cheaper here; you want a price that survives titration; you'll prepay for the $297 effective rate. Neither answer is universal — which is the argument for choosing from data with dates on it rather than from whichever ad loaded first.

If neither one fits

Two programs never exhaust the market — the nearest substitutes on the verified board are Fridays at $359 (flat, no membership); MEDVi at $399 (flat, no membership); Remedy Meds at $399 (flat, no membership) — or skip straight to the rankings page, where every standard “cheapest / best / no-commitment” question is answered in one sourced sentence.

The brand benchmark both must beat

Neither program exists in a vacuum: FDA-approved Zepbound sits at $449/month at maintenance (LillyDirect or retail KwikPens, ~$350 on TrumpRx, ~$50 for newly eligible Medicare patients), and Wegovy at a flat $349. The cheaper of these two compounded options saves $1,200/year against the Zepbound benchmark — the number that has to justify accepting a not-FDA-reviewed product, per the full trade analysis. When a compounded quote drifts above ~$350, this benchmark starts winning the argument on its own.

The verdict

On the numbers alone, Henry Meds is the cheaper tirzepatide program by $59/mo. Both records, with dates and sources, live in the pricing database.